Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Pharmaceuticals

Market Closed - Japan Exchange 11:30:00 19/07/2024 am IST 5-day change 1st Jan Change
3,460 JPY -0.12% Intraday chart for Nippon Shinyaku Co., Ltd. -2.92% -30.74%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy MT
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100 CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate MT
Jefferies Adjusts Nippon Shinyaku’s Price Target to 6,900 Yen From 6,700 Yen, Keeps at Buy MT
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023 CI
Jefferies Adjusts Nippon Shinyaku's Price Target to 6,700 Yen From 7,700 Yen, Keeps at Buy MT
Jefferies Upgrades Nippon Shinyaku to Buy From Hold, Adjusts Price Target to 7,700 Yen From 6,400 Yen MT
Nippon Shinyaku Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Jefferies Adjusts Nippon Shinyaku's Price Target to 6,400 Yen From 7,300 Yen, Keeps at Hold MT
Capricor Therapeutics Signs Commercialization, Distribution Deal With Nippon Shinyaku in Japan MT
Capricor Therapeutics, Nippon Shinyaku Enter Marketing Deal for Duchenne Muscular Dystrophy Treatment in US MT
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of Cap-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S CI
Clinigen JV To Launch Viltepso Managed Access Program For Duchenne Muscular Dystrophy Patients MT
Clinigen Group plc Signs Agreement with Nippon Shinyaku CI
Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku CI
Zogenix : Secures Orphan Drug Designation for Fintepla in Japan MT
Nippon Shinyaku Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2021 CI
Nippon Shinyaku Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2021 CI
Nippon Shinyaku Co., Ltd. Announces Dividend for the Year Ended March 31, 2021, Scheduled Start of Payment June 30, 2021; Provides Dividend Guidance for the Second Quarter and Fiscal Year 2022 CI
Menarini Group and Nippon Shinyaku Co., Ltd. Enter into an Exclusive License Agreement to Develop and Commercialize Elzonris® (Tagraxofusp) in Japan CI
Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the Third Quarter Ended December 31, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020 CI
Nippon Shinyaku Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2020 CI
Nippon Shinyaku Co., Ltd.(TSE:4516) added to S&P Japan Mid Cap 100 CI
Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 5, 2019; Provides Dividend Guidance for the Full Year Ending March 31, 2020 CI
Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Earnings Guidance for the First Half and Full Year of 2019 CI
Chart Nippon Shinyaku Co., Ltd.
More charts
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3,460 JPY
Average target price
3,987 JPY
Spread / Average Target
+15.24%
Consensus
  1. Stock Market
  2. Equities
  3. 4516 Stock
  4. News Nippon Shinyaku Co., Ltd.
  5. Jefferies Adjusts Nippon Shinyaku's Price Target to 6,400 Yen From 7,300 Yen, Keeps at Hold